SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO 1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate
Brightplex technology, acquired from HalioDx , is designed to help drug developers understand and leverage the tumor micro-environment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing
- First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation
- Findings from Analysis Evaluating Test In Newly Diagnosed, Clinically High-Risk Disease to be Highlighted in ASTRO Press Program - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data further validating the clinical utility of the
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9 . Company management will host a conference call and webcast to
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
